Retrospective cohort study reveals combined effects of antimicrobial resistance and cytogenetic risk on survival outcomes in AML patients undergoing chemotherapy.
Key Points
Patients with antimicrobial resistance showed significantly shorter overall survival compared to non-colonized patients.
MDRGN colonization was linked to a median overall survival of just 3.53 months, significantly lower than 18.83 months for those without colonization.
High-risk cytogenetic status was associated with independently reduced overall survival, indicating its prognostic importance in AML.
The combined impact of antimicrobial resistance and high-risk cytogenetics was shown to worsen prognosis in acute myeloid leukemia patients.